DOTFE

DOTFE, also known as 4-(2,2,2-trifluoroethyl)-2,5-dimethoxyamphetamine, is a drug of the phenethylamine, amphetamine, and DOx families.^[1][2][3] It is a close analogue of known psychedelics like the DOx psychedelic DOTFM and the 2C psychedelics 2C-TFE and 2C-TFM.^[1][3][2] The drug was predicted to bind to the serotonin 5-HT_2A receptor, with a predicted affinity (K_i) of 50 nM.^[2] It was inactive in humans at doses of up to 3 mg, but higher doses were not assessed.^[1][3] DOTFE is expected to be a potent psychedelic at active doses.^[1] It was first described in the scientific literature by at least 1999.^[2] DOTFE was evaluated in humans by Daniel Trachsel, with these reports published in 2012 and 2013.^[3][1]

DOTFE

Clinical data
Other names	4-(2,2,2-Trifluoroethyl)-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-(2,2,2-trifluoroethyl)amphetamine
ATC code	None
Identifiers
IUPAC name 1-[2,5-dimethoxy-4-(2,2,2-trifluoroethyl)phenyl]propan-2-amine
PubChem CID	170143488
Chemical and physical data
Formula	C13H18F3NO2
Molar mass	277.287 g·mol−1
3D model (JSmol)	Interactive image
SMILES COc1cc(CC(F)(F)F)c(cc1CC(N)C)OC
InChI InChI=1S/C13H18F3NO2/c1-8(17)4-9-5-12(19-3)10(6-11(9)18-2)7-13(14,15)16/h5-6,8H,4,7,17H2,1-3H3 Key:OZFGHDLWUVVAPY-UHFFFAOYSA-N

See also

• DOx (psychedelics)